Background: To date, no predictive factors are recognized and applied in the therapeutic
choice for metastatic renal cell carcinoma. Due to significant side-effects and costs, which …

Background The aim of this study is to investigate the prognostic relevance of the best
objective response of metastatic target lesions during sunitinib treatment in patients with …

Aim: To identify tissue biomarkers that are predictive of the therapeutic effect of sunitinib in
treatment of metastatic clear cell renal cell carcinoma (mCRCC). Materials and Methods: Our …

Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an
advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple …

Although sunitinib shows a high response rate in patients with untreated metastatic renal
cell carcinoma (mRCC), quite a few patients show no therapeutic effect. Therefore, it is …

Background Preliminary studies suggested that selected drug-related toxicities of sunitinib
may correlate with a better prognosis. Patients and Methods From January 2006 through …

Purpose: Previous reports showed that targeted therapy efficacy varied due to different
metastatic organs in patients with metastatic renal cell carcinoma (mRCC). This study aimed …

Sunitinib is an orally‐administered, multitargeted tyrosine kinase inhibitor. The main targets
are vascular endothelial growth factor receptor (VEGFR)‐1, VEGFR‐2, VEGFR‐3, platelet …

Background Patients with metastatic clear cell renal cell carcinoma (ccRCC) are frequently
treated with tyrosine kinase inhibitors (TKI) such as sunitinib. It inhibits angiogenic pathways …

e16097 Background: Although hypothyroidism is a well-known adverse effect of sunitinib in
western patients (pts) with metastatic renal cell carcinoma (MRCC), the effects on thyroid …